XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
The Company has historically incurred significant operating losses and experienced negative cash flows from operations. The Company continues expansion of the ELIMINATE-B clinical trial to higher dose levels and is preparing to file an investigational new drug and/or clinical trial application for the PBGENE-DMD program. In July 2025, the Company initiated operating efficiencies, including employment related and other expense reductions, to reduce annual operating expenses and extend its cash runway.